Glaukos Corp. became available for public trade today on the NYSE. The company was looking to raise $75 million and had a price target of $13 to $15 per share, but its final IPO price was increased to $18 per share this morning. JPMorgan (JPM- Analyst Report), Bank of America’s (BAC - Analyst Report) Merrill Lynch, and Goldman Sachs (GS - Analyst Report) served as the lead underwriters on the deal.
           
The company’s stock opened at $29.11 per share, and by market close had increased to $31.22, a 73.44% increase from its initial price of $18. The company was able to raise $118 million.
           
Based in Laguna Hills, California, Glaukos is an ophthalmic medical tech company whose focus is on surgical devices for treating the disease glaucoma. It posted revenue of $14.66 million last year, with a net loss of $1.46 million.

Glaukos success shows that the healthy IPO market continues, as it joins the list of the many companies which have seen major success in their first day of public trading. There are several more IPOs to come, as June continues to be a month in which IPOs have been abundant (also read: 5 Upcoming Healthcare IPOs: What Investors Should Know).